Patients with ALK+ NSCLC often have brain metastases; thus, American Society of Clinical Oncology and ESMO guidelines recommend TKIs effective in the brain and suggest avoiding local therapy initially owing to the strong brain activity of ALK inhibitors [63, 64]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.